Market revenue in 2023 | USD 342.9 million |
Market revenue in 2030 | USD 453.0 million |
Growth rate | 4.1% (CAGR from 2023 to 2030) |
Largest segment | Cannabis/marijuana |
Fastest growing segment | Cannabis/Marijuana |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Other Drug Types |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Clinical Reference Laboratory, Cordant Health Solutions, ZeOmega, Psychemedics Corp, Millennium HealthCare Inc, Mayo Clinic, Precision Diagnostics, LGC Group, Labcorp Drug Development, Legacy Medical, Drugscan, USDTL |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug of abuse testing services market will help companies and investors design strategic landscapes.
Cannabis/marijuana was the largest segment with a revenue share of 24.29% in 2023. Horizon Databook has segmented the UK drug of abuse testing services market based on alcohol, cannabis/marijuana, cocaine, opioids, amphetamine & methamphetamine, lsd, other drug types covering the revenue growth of each sub-segment from 2018 to 2030.
According to a study published by Trades Union Congress (TUC), in February 2018, Britain’s workplace drug testing was mainly used in safety-critical fields, such as energy generation and transport. The same source stated an increased use of workplace testing in the construction industry, which is anticipated to support the market during the forecast period.
In March 2015, a new law on driving under the influence of drugs came into effect in England and Wales. This law was linked to drug testing and is anticipated to boost the demand for testing services in the country.
Furthermore, according to data published by EMCDDA, in 2017, around 12.3% of young adults (16 to 34 years) in England and Wales used cannabis last year, and around 4.7% and 3.3% of young adults used cocaine and MDMA (ecstasy/molly), respectively. This high prevalence of drug abuse in the country is anticipated to boost the demand for testing services, thus, driving the market.
Horizon Databook provides a detailed overview of country-level data and insights on the UK drug of abuse testing services market , including forecasts for subscribers. This country databook contains high-level insights into UK drug of abuse testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account